| GTO ID | GTC2598 |
| Trial ID |
NCT04765657
|
| Disease |
Familial Hypercholesterolemia
|
| Altered gene | PCSK9 |
| Therapeutic/Target gene | Target gene |
| Therapy | siRNA |
| Treatment | ALN-PCSSC|Inclisiran|KJX839|Leqvio |
| Location approved | EU, UK, Australia, Canada, Israel, US, Saudi Arabia, Japan, China |
| Phase | Phase3 |
| Recruitment status | Active, Not Recruiting |
| Title | A Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled Study to Evaluate the Efficacy and Safety of Inclisiran in Asian Patients With ASCVD or ASCVD High Risk and Elevated Low-density Lipoprotein Cholesterol as an Adjunct to Diet and Maximally Tolerated Statins With or Without Additional Lipid-lowering Therapy (ORION-18) |
| Year | 2021 |
| Country | China|Korea,Republic of|Singapore|China |
| Company sponsor | Novartis Pharmaceuticals |
| Other ID(s) | CKJX839A12307 |